Biotechnology Sector

Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.

This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.

The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.

Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets  The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.

Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.

There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.

Industry News

  • India’s Growing Importance in Generic Drug API Manufacturing
    by DrugPatentWatch on December 10, 2024 at 9:46 pm

    India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic Source

  • The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing
    by DrugPatentWatch on December 10, 2024 at 9:09 pm

    The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of Source

  • How CDMOs Can Help with Regulatory Challenges
    by DrugPatentWatch on December 10, 2024 at 7:38 pm

    The pharmaceutical and biotechnology industries are heavily regulated, and navigating these regulations can be a significant challenge for companies, especially Source

  • The Role of Scientific Expertise in Generic Drug Development
    by DrugPatentWatch on December 10, 2024 at 6:48 pm

    Generic drug development is a complex process that involves not only scientific and medical expertise but also adherence to strict Source

  • Analyzing the impact of biosimilars on biologic drug manufacturing technologies
    by DrugPatentWatch on December 10, 2024 at 4:46 pm

    Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, Source

  • The Importance of Regulatory Expertise in Generic Drug Development
    by DrugPatentWatch on December 10, 2024 at 3:47 pm

    Generic drug development is a complex process that requires a deep understanding of regulatory requirements and guidelines. Regulatory expertise plays Source

  • Biotech in 2024: A retrospective
    by Jules Adam on December 10, 2024 at 2:00 pm

    2024 is coming to a close and it is time to look at how biotech performed this year. Was it a triumph or a year of cautious optimism? The post Biotech in 2024: A retrospective appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • How do patent thickets vary across different countries
    by DrugPatentWatch on December 10, 2024 at 1:28 pm

    Patents play a crucial role in protecting intellectual property and fostering innovation. However, the increasing complexity of patent systems has Source

  • How to Use Convertible Debt for Biotech Financing
    by Yali Friedman on December 10, 2024 at 12:27 pm

    How to Use Convertible Debt for Biotech Financing Convertible debt is a financing option that has gained popularity among biotech Source

  • How the right clinical trial design software boosts success rates
    by Jennifer Tsang on December 10, 2024 at 9:00 am

    Discover key challenges in clinical trial design and learn how selecting the right software solution can significantly enhance the likelihood of trial success. The post How the right clinical trial design software boosts success rates appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Overcoming challenges in biosimilar analytical characterization
    by DrugPatentWatch on December 9, 2024 at 7:28 pm

    Biosimilars have faced significant challenges in their analytical characterization. This process involves a comprehensive analysis of the biosimilar’s molecular structure, Source

  • Pharmacognosy and Drug Patents: Unveiling Nature’s Medicinal Treasures
    by DrugPatentWatch on December 9, 2024 at 2:23 pm

    In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This Source

  • CAR-T cell therapy for lupus: An emerging field with great potential
    by Willow Shah-Neville on December 9, 2024 at 2:00 pm

    Discover how the emerging field of using CAR-T cell therapy to treat lupus could offer a potential cure for the autoimmune disorder. The post CAR-T cell therapy for lupus: An emerging field with great potential appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • How to Leverage Government Grants for Biotech Projects
    by Yali Friedman on December 9, 2024 at 1:03 pm

    How to Leverage Government Grants for Biotech Projects Introduction Navigating the Complex World of Biotech Funding Biotech startups face a Source

  • Handling Drug Patent Invalidity Claims
    by DrugPatentWatch on December 8, 2024 at 11:51 pm

    The pharmaceutical industry is heavily reliant on patents to protect intellectual property and maintain market exclusivity. However, with the increasing Source

  • DrugChatter: Aurobindo klonopin ok?
    by DrugChatter on December 8, 2024 at 10:51 am

    Aurobindo Klonopin: A Comprehensive Review Introduction Klonopin, also known as clonazepam, is a medication commonly prescribed... https://www.Drugchatter.com/chat/56192/aurobindo-klonopin-ok/ Source

  • Cracking the code of biotech valuations
    by Jim Cornall on December 6, 2024 at 9:00 am

    Our guest on the podcast this week to discuss the biotech scene in Eastern Europe, and look at some of the challenges facing biotech companies is Adam Marťák, CEO of ambiom. The post Cracking the code of biotech valuations appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Top 5 Biotech Funding Sources for Small Companies
    by Yali Friedman on December 5, 2024 at 7:12 pm

    Top 5 Biotech Funding Sources for Small Companies The biotech industry is booming, with funding skyrocketing in recent years. For Source

  • Understanding the Lifecycle of Generic Drugs: From Development to Market Impact
    by DrugPatentWatch on December 5, 2024 at 4:21 pm

    In the ever-evolving landscape of healthcare, generic drugs play a crucial role in providing affordable and accessible medication to millions Source

  • The biggest private biotech investments in November 2024
    by Willow Shah-Neville on December 5, 2024 at 2:00 pm

    The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024. The post The biggest private biotech investments in November 2024 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Five biosimilar companies you should know about
    by Willow Shah-Neville on December 5, 2024 at 9:00 am

    Discover five biosimilar companies creating affordable versions of blockbuster drugs and hoping to capitalize on the upcoming patent cliff. The post Five biosimilar companies you should know about appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Drug Patent Expirations for the Week of December 1, 2024
    by DrugPatentWatch – Make Better Decisions on December 5, 2024 at 5:06 am

    SUMAVEL DOSEPRO (sumatriptan succinate) Endo operations Patent: 8,287,489 Expiration: Dec 6, 2024 See More … For more information on how Source

  • Optimizing Generic Drug Development with Machine Learning
    by DrugPatentWatch on December 4, 2024 at 3:12 pm

    Introduction The pharmaceutical industry is undergoing a significant transformation with the advent of machine learning methods. These methods have the Source

  • Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments
    by Roohi Mariam Peter on December 4, 2024 at 2:10 pm

    There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner. The post Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • How Biotechnology is Transforming the Bioengineering Landscape
    by Yali Friedman on December 4, 2024 at 2:06 pm

    How Biotechnology is Transforming the Bioengineering Landscape Introduction Biotechnology, the intersection of biology and technology, is revolutionizing various sectors, including Source

  • DrugChatter: Is ozempic covered by insurance?
    by DrugChatter on December 4, 2024 at 6:49 am

    Is Ozempic Covered by Insurance? A Comprehensive Guide As a medication used to treat type 2 diabetes, Ozempic has become... https://www.Drugchatter.com/chat/24632/is-ozempic-covered-by-insurance/ Source

  • Understanding Equity Financing in Biotech
    by Yali Friedman on December 3, 2024 at 3:09 pm

    Understanding Equity Financing in Biotech Equity financing is a crucial component of the biotech industry, enabling startups to secure the Source

  • Twelve gift ideas for a biotech enthusiast this holiday season
    by Roohi Mariam Peter on December 3, 2024 at 2:00 pm

    Explore our curated list of biotechnology-themed gifts, ranging from captivating board games to engaging DIY biology kits. The post Twelve gift ideas for a biotech enthusiast this holiday season appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Process intensification: Fueling biopharma success at warp speed
    by Will Chu on December 3, 2024 at 9:00 am

    Learn about process intensification in biopharma, key strategies for success, and solutions to overcome manufacturing challenges. The post Process intensification: Fueling biopharma success at warp speed appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • The rise of cancer vaccines: A new era in immunotherapy
    by Jules Adam on December 2, 2024 at 2:00 pm

    Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors. The post The rise of cancer vaccines: A new era in immunotherapy appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Trump’s healthcare picks: Who they are and what they mean for the biopharma industry 
    by Roohi Mariam Peter on November 29, 2024 at 2:10 pm

    Trump's nominees for top healthcare roles have sparked significant debate. So, what do their appointments signal for the future of healthcare in the U.S.? The post Trump’s healthcare picks: Who they are and what they mean for the biopharma industry  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • Can biotech beat mosquito-borne diseases?
    by Jim Cornall on November 29, 2024 at 9:00 am

    With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes. The post Can biotech beat mosquito-borne diseases? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

  • A new, updated account of poroid fungi in North America
    on September 4, 2024 at 6:31 pm

    Poroid fungi, commonly known as “polypores,” are among the most frequently encountered fungi throughout the year because of their large size and longevity. Despite the common presence of poroid fungi in North America, most guides include only a limited selection of these fungi. Poroid Fungi of North America, by Leif Ryvarden, offers a necessary, updated account

  • Few anti-immigration users dominate most of UK-based anti-immigration content on Twitter with rapid spread and high polarization
    on September 4, 2024 at 6:25 pm

    A study of more than 200,000 tweets from 2019 and 2020 finds that anti-immigration content spreads faster than pro-immigration tweets and that a few users disproportionally generated most of the UK-based anti-immigration content. Andrea Nasuto and Francisco Rowe of the Geographic Data Science Lab at the University of Liverpool, UK, present these findings in the

  • Agriculture accelerated human genome evolution to capture energy from starchy foods
    on September 4, 2024 at 6:23 pm

    Over the past 12,000 years, humans in Europe have dramatically increased their ability to digest carbohydrates, expanding the number of genes they have for enzymes that break down starch from an average of eight to more than 11, according to a new study by researchers from the U.S., Italy and United Kingdom. Credit: Peter Sudmant,

  • As dogs age, their owner-assessed quality of life predictably declines, with higher mortality seen at quality of life below 76% of the maximum score – though many dogs have high quality of life even when at predicted lifespan
    on September 4, 2024 at 6:19 pm

    As dogs age, their owner-assessed quality of life predictably declines, with higher mortality seen at quality of life below 76% of the maximum score – though many dogs have high quality of life even when at predicted lifespan Credit: Juli Leonard for the Canine Neuroaging Program, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/) As dogs age, their owner-assessed quality

  • Samples from bottled water, tap water and household-treated tap water in San Francisco Bay Area indicate that all sources may have potential health risks, largely from trihalomethanes
    on September 4, 2024 at 6:17 pm

    Samples from bottled water, tap water and household-treated tap water in San Francisco Bay Area indicate that all sources may have potential health risks, largely from trihalomethanes. Credit: SimpleLab, Inc. Redistribution permitted with credit given to the creator, SimpleLab, Inc. Samples from bottled water, tap water and household-treated tap water in San Francisco Bay Area

  • Young male northern elephant seals are captured on camera returning to a deep sea cabled observatory off Canada’s British Columbia coast, demonstrating new insight into fish foraging behavior
    on September 4, 2024 at 6:13 pm

    Young male northern elephant seals are captured on camera returning to a deep sea cabled observatory off Canada’s British Columbia coast, demonstrating new insight into fish foraging behavior Credit: Ocean Networks Canada, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/) Young male northern elephant seals are captured on camera returning to a deep sea cabled observatory off Canada’s British Columbia

  • Both cats and dogs often enjoy playing fetch with their owners
    on September 4, 2024 at 6:11 pm

    Although more common in dogs, 4 in 10 pet cats also choose to play fetch with their owners, Mikel Delgado from Purdue University, US, and colleagues report in the open-access journal PLOS ONE, publishing September 4, 2024. Credit: Leeza Kolesnikov, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/) Although more common in dogs, 4 in 10 pet cats also choose

  • Collaborative research to benefit coastal flounder populations and fishers
    on September 4, 2024 at 6:09 pm

    Four faculty members from three departments in the College of Natural Resources and Environment have received $1.7 million from the National Science Foundation to fund research into the dynamics of socio-environmental factors impacting coastal fisheries. Credit: Photo by Lee Friesland for Virginia Tech. Four faculty members from three departments in the College of Natural Resources

  • New book ‘Macroevolutionaries’ explores intersection of evolution, art and popular culture
    on September 4, 2024 at 5:13 pm

    LAWRENCE — A new book of natural history essays co-written by a University of Kansas paleontologist has been published by Columbia University Press. Credit: Columbia University Press LAWRENCE — A new book of natural history essays co-written by a University of Kansas paleontologist has been published by Columbia University Press. Bruce Lieberman, Dean’s Professor of Evolutionary Biology

  • SpinMagIC: ‘EPR on a chip’ ensures quality of olive oil and beer
    on September 4, 2024 at 5:10 pm

    The first sign of spoilage in many food products is the formation of free radicals, which reduces the shelf-life and the overall quality of the food. Until now, the detection of these molecules has been very costly for the food companies. Researchers at HZB and the University of Stuttgart have developed a portable, small and

  • City of Hope to offer second opinions for cancer patients in Southeast Asia via a collaboration agreement with the Healthway Cancer Care Hospital
    on September 4, 2024 at 5:08 pm

    LOS ANGELES — Oncology specialists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, can now provide leading-edge clinical guidance to patients living in Southeast Asia through a second opinion collaboration agreement with the Healthway Cancer Care Hospital, the first comprehensive cancer hospital in

  • A new role for intelligent tutors powered by AI in brain surgery? 
    on September 4, 2024 at 4:17 pm

    Neurosurgery is perhaps one of the most demanding professions in healthcare. Surgeons spend long hours performing operations where expert performance means the difference between a good and bad patient outcome. While operative injuries are rare, when they occur, they can have serious, and lifelong consequences.    Credit: The Neuro Neurosurgery is perhaps one of the most

  • At-risk butterflies more likely to survive with human help
    on September 4, 2024 at 4:11 pm

    VANCOUVER, Wash. –  Some of the butterflies most in danger of fluttering out of existence fare better when their habitats are actively managed by humans, a recent study found. Credit: Photo by Shelly Hanks, Washington State University VANCOUVER, Wash. –  Some of the butterflies most in danger of fluttering out of existence fare better when

  • PFAS influence the development and function of the brain
    on September 4, 2024 at 4:07 pm

    Because of their special properties – heat resistance, water and grease repellence, and high durability – PFAS are used in many everyday products (e.g. cosmetics, outdoor clothing, and coated cookware). But it is precisely these properties that make them so problematic. “Because some PFAS are chemically stable, they accumulate in the environment and enter our